Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases

  • Received : 2018.01.21
  • Accepted : 2018.03.13
  • Published : 2018.12.25
⟨ Previous Next ⟩

Abstract

Backgrounds/Aims: The objective of our study was to determine the epidemiological, laboratory, and serological characteristics of patients with chronic hepatitis B virus (HBV) infection and normal transaminases. The study also aimed to evaluate liver damage by measuring the liver fibrosis (LF) grade and to identify possible factors associated with the presence of fibrosis. Methods: A retrospective observational study was conducted in patients with chronic HBV infection and classified as inactive carriers or immune-tolerant. Epidemiological variables of age, sex, immigrant, alcohol consumption, and body mass index (BMI), as well as virological variables (HBV DNA) and transaminase level were collected throughout the follow-up. The LF grade was evaluated by transient elastography. The cutoff value for significant fibrosis (SF) was liver stiffness ${\geq}7.9kPa$. Results: A total of 214 patients were included in the analysis, and 62% of them had a BMI ${\geq}25kg/m^2$. During follow-up, 4% of patients showed transaminase elevation (<1.5 times normal). Most patients had a viral DNA level <2,000 IU/mL (83%). Data on LF were available in 160 patients; of these, 14% had SF, 9% F3, and 6% F4. The variables associated with the presence of SF were transaminase alteration during follow-up, as 23% of patients with SF had elevated transaminases versus 3% of patients without SF (P<0.005), and BMI, as the vast majority of patients with SF (88%) had a BMI ${\geq}25kg/m^2$ versus 56% of patients without SF (P<0.05). Conclusions: In patients with chronic HBV infection and normal transaminases, liver damage does not seem to be related to DNA levels, alcohol consumption, or immigrant status. SF seems to be associated with transaminase alteration during follow-up and elevated BMI. It is therefore recommended to measure LF grade with validated non-invasive methods in such patients.

Keywords

References

  1. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007;147:58-61. https://doi.org/10.7326/0003-4819-147-1-200707030-00010
  2. Guardiola Arevalo A, Gomez Rodriguez R, Romero Gutierrez M, Gomez Moreno AZ, Garcia Vela A, Sanchez Simon R, et al. Characteristics and course of chronic hepatitis B e antigen-negative infection. Gastroenterol Hepatol 2017;40:59-69. https://doi.org/10.1016/j.gastrohep.2016.11.002
  3. Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2002;57:196-202.
  4. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130-141. https://doi.org/10.1055/s-2006-939751
  5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242. https://doi.org/10.1016/j.jhep.2008.10.001
  6. Hu KQ. Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population? Am J Gastroenterol 2008;103:1824-1833. https://doi.org/10.1111/j.1572-0241.2008.01878.x
  7. Buti M, Garcia-Samaniego J, Prieto M, Rodriguez M, Sanchez Tapias JM, Suarez E, et al. Consensus document of the Spanish Association for the Study of the Liver on the treatment of Hepatitis B infection (2012). Gastroenterol Hepatol 2012;35:512-528. https://doi.org/10.1016/j.gastrohep.2012.04.006
  8. Perrillo R. Hepatitis B virus replication x time equals trouble. Gastroenterology 2006;130:989-991. https://doi.org/10.1053/j.gastro.2006.01.070
  9. Gomez Rodriguez R, Guardiola Arevalo A, Gomez Moreno AZ, Garcia Vela A, Gomez Hernando C, Rodriguez Merlo R, et al. Characteristics of patients with chronic hepatitis B virus infection. Analysis of a series of 474 patients. Gastroenterol Hepatol 2013;36:243-253. https://doi.org/10.1016/j.gastrohep.2012.10.006
  10. Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002;36:543-546. https://doi.org/10.1016/S0168-8278(02)00004-1
  11. Invernizzi F, Vigano M, Grossi G, Lampertico P. The prognosis and management of inactive HBV carriers. Liver Int 2016;36 Suppl 1:100-104.
  12. Lin CL, Liao LY, Liu CJ, Yu MW, Chen PJ, Lai MY, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology 2007;45:1193-1198. https://doi.org/10.1002/hep.21585
  13. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134:1376-1384. https://doi.org/10.1053/j.gastro.2008.02.075
  14. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009;49:1017-1044. https://doi.org/10.1002/hep.22742
  15. Castellano G, Manzano ML. The value of FibroScan(R) in the followup of patients with chronic hepatitis B virus infection without indication for treatment. Gastroenterol Hepatol 2014;37 Suppl 2:15-21. https://doi.org/10.1016/S0210-5705(14)70064-0
  16. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500. https://doi.org/10.1056/NEJM200102153440706
  17. Wong VW, Chan HL. Transient elastography. J Gastroenterol Hepatol 2010;25:1726-1731. https://doi.org/10.1111/j.1440-1746.2010.06437.x
  18. Castera L, Negre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology 1999;30:1529-1530. https://doi.org/10.1002/hep.510300624
  19. Castera L, Negre I, Samii K, Buffet C. Patient administered nitrous oxide/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: a randomized placebo-controlled trial. Am J Gastroenterol 2001;96:1553-1557. https://doi.org/10.1016/S0002-9270(01)02339-5
  20. Chan HL, Wong GL, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Alanine aminotransferase based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009;16:36-44. https://doi.org/10.1111/j.1365-2893.2008.01037.x
  21. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen negative chronic hepatitis B using transient elastography. Am J Gastroenterol 2008;103:3071-3081. https://doi.org/10.1111/j.1572-0241.2008.02157.x
  22. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol 2009;7:227-233. https://doi.org/10.1016/j.cgh.2008.10.023
  23. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther 2011;16:165-172. https://doi.org/10.3851/IMP1726
  24. Castera L, Bernard PH, Le Bail B, Foucher J, Trimoulet P, Merrouche W, et al. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther 2011;33:455-465. https://doi.org/10.1111/j.1365-2036.2010.04547.x
  25. Chon YE, Choi EH, Song KJ, Park JY, Kim DY, Han KH, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One 2012;7:e44930. https://doi.org/10.1371/journal.pone.0044930
  26. Vigano M, Paggi S, Lampertico P, Fraquelli M, Massironi S, Ronchi G, et al. Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. Aliment Pharmacol Ther 2011;34:353-362. https://doi.org/10.1111/j.1365-2036.2011.04722.x
  27. Fateen AA, Shahin RY, Farres MN, Eldeeb MA, Amer HA. Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt. Ann Hepatol 2012;11:464-470. https://doi.org/10.1016/S1665-2681(19)31459-0
  28. Mena A, Pedreira JD, Castro A, Lopez S, Vazquez P, Poveda E. Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers. J Gastroenterol Hepatol 2014;29:173-178. https://doi.org/10.1111/jgh.12432
  29. Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. J Gastroenterol Hepatol 2013;28:1842-1848. https://doi.org/10.1111/jgh.12327
  30. Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross sectional study of Asians in California. Hepatology 2007;46:1034-1040.
  31. Cadranel JF, Lahmek P, Causse X, Bellaiche G, Bettan L, Fontanges T, et al. Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis--results of a nationwide survey. Aliment Pharmacol Ther 2007;26:565-576. https://doi.org/10.1111/j.1365-2036.2007.03400.x
  32. Poves-Martinez E, del Pozo-Prieto D, Costero-Pastor B, Borrego- Rodriguez G, Beceiro-Pedrono I, Sanz-Garcia C, et al. Diagnostic incidence of the presence of positive HBsAg: epidemiologic, clinical, and virological characteristics. Rev Esp Enferm Dig 2012;104:10-15. https://doi.org/10.4321/S1130-01082012000100003
  33. Fabris P, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, et al. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol 2008;42:527-532. https://doi.org/10.1097/MCG.0b013e318030e3ab
  34. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57(RR-8):1-20.
  35. Oliveri F, Coco B, Ciccorossi P, Colombatto P, Romagnoli V, Cherubini B, et al. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol 2008;14:6154-6162. https://doi.org/10.3748/wjg.14.6154
  36. Sola R , Cruz De Castro E, Hombrados M, Planas R, Coll S, Jardi R, et al. Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study. Med Clin (Barc) 2002;22:90-95.
  37. Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008;48:1451-1459. https://doi.org/10.1002/hep.22518
  38. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008;15:434-441. https://doi.org/10.1111/j.1365-2893.2007.00957.x
  39. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, et al. Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase. Am J Med 2006;119:977-985. https://doi.org/10.1016/j.amjmed.2006.04.036
  40. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009;58:111-117. https://doi.org/10.1136/gut.2008.157735
  41. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475. https://doi.org/10.1016/S0140-6736(12)61425-1

Cited by

  1. Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level vol.24, pp.4, 2018, https://doi.org/10.3350/cmh.2018.1008
  2. Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co‐infected Adults vol.71, pp.2, 2018, https://doi.org/10.1002/hep.30825
  3. A different detection method reveals a new role of alanine aminotransferase as an indicator of liver fibrosis vol.35, pp.2, 2018, https://doi.org/10.3904/kjim.2020.050
  4. Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir vol.27, pp.10, 2018, https://doi.org/10.1111/jvh.13316
  5. The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma vol.10, pp.None, 2018, https://doi.org/10.7554/elife.69679
  6. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B vol.27, pp.2, 2021, https://doi.org/10.3350/cmh.2020.0216